Home  /  Resource Library  /  Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE

ASCO 2019: Results of a study measuring patient reported outcomes in patients with Waldenstrom’s Macroglobulinemia treated with ibrutinib combined with rituximab.